http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011203050-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b6121dedd894b3f760906b68697d616 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2011-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2911795ad20799396d11b1b89200b3b7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_245d4a7db0c7d843a7cf06c44fe835b1 |
| publicationDate | 2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2011203050-A1 |
| titleOfInvention | Method for treatment with bucindolol based on genetic targeting |
| abstract | Abstract The present invention concerns the use of methods of treating a patient with bucindolol, particularly a patient with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the p l adrenergic receptor (AR). |
| priorityDate | 2004-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1451.